Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Free Cash Flow: 2013-2025

Historic Free Cash Flow for Theravance Biopharma (TBPH) over the last 13 years, with Sep 2025 value amounting to -$6.5 million.

  • Theravance Biopharma's Free Cash Flow fell 24.89% to -$6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $243.5 million, marking a year-over-year increase of 2078.82%. This contributed to the annual value of -$11.9 million for FY2024, which is 59.75% up from last year.
  • Theravance Biopharma's Free Cash Flow amounted to -$6.5 million in Q3 2025, which was down 103.13% from $208.1 million recorded in Q2 2025.
  • Theravance Biopharma's 5-year Free Cash Flow high stood at $208.1 million for Q2 2025, and its period low was -$124.3 million during Q4 2022.
  • In the last 3 years, Theravance Biopharma's Free Cash Flow had a median value of -$2.5 million in 2023 and averaged $18.5 million.
  • Per our database at Business Quant, Theravance Biopharma's Free Cash Flow tumbled by 172.07% in 2022 and then surged by 4,774.77% in 2025.
  • Over the past 5 years, Theravance Biopharma's Free Cash Flow (Quarterly) stood at -$45.7 million in 2021, then crashed by 172.07% to -$124.3 million in 2022, then spiked by 98.77% to -$1.5 million in 2023, then increased by 28.67% to -$1.1 million in 2024, then decreased by 24.89% to -$6.5 million in 2025.
  • Its Free Cash Flow stands at -$6.5 million for Q3 2025, versus $208.1 million for Q2 2025 and $43.0 million for Q1 2025.